NR4A2 and Parkinson disease: The Nurr1 agonists amodiaquine, hydroxychloroquine, and SA00025 have been shown to attenuate deficits in animal models of Parkinson’s disease (Kim et al., 2015; Smith et al., 2015; Hedya et al., 2019).